Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...

Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for ...

The FDA updated a warning on the label of esketamine nasal spray (Spravato) about the long-term cognitive ... for agitation ...

An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...

New research offers hope for delaying Alzheimer’s disease progression by years after initial diagnosis. Alzheimer’s disease is a leading cause of death among those aged 65 or older. As the most common ...

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...

A new therapy may delay Alzheimer's disease progression by years, according to a study by researchers at Texas A&M University ...

Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

The funding will be paid across five years with the first year provided by Moody Medical Research Institute and the following four from the Moody Foundation.

So investigators set out to examine the cost-effectiveness and health equity impact of a hypothetical Alzheimer’s disease-modifying treatment on more than 3.1 million Americans.